La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Neumora Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Neumora Therapeutics..

Neumora Therapeutics (NASDAQ:NMRA) Azioni, Catena delle Opzioni

Neumora Therapeutics

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics Inc

Earnings

Earnings Beats

News

CEVA

CEVA Q3 2024 Adj. EPS $0.14 Beats $0.10 Estimate, Sales $27.207M Beat $26.850M Estimate

Needham analyst Laura Martin reiterates Perion Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PERI#NASDAQ">PERI</a>) with a Hold.

Reiteration

Analyst Ratings

PERI

Needham Reiterates Hold on Perion Network

Virgin Galactic Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) shares closed up 3.5% on Wednesday after the company reported a net loss of $75 million for the third quarter, lower than the $105 million net loss reported in the corresponding period last year owing to lower operating expenses.
What Happened: Branson&#8217;s spaceflight company&#8217;s total operating expenses fell to $82.1 million in the third quarter from $116 million in the corresponding quarter a year ago. However, revenue also fell to $0.4 million from $1.7 million last year owing to the pause in commercial spaceflights.
Virgin Galactic is now focussing its efforts on the production of the Delta Class spaceships. The new spaceships remain on track to enter commercial service in 2026, the company said.
Delta Class will&nbsp;<a href="https://www.benzinga.com/news/24/06/39247906/planes-just-cant-compete-elon-musk-boasts-rocket-booster-superiority-after-richard-bransons-virgin-g" target="_blank" rel="noreferrer noopener">replace the company's VSS Unity spaceplane</a>&nbsp;which had its last commercial flight in the second quarter. 
Announces At-The-Market Equity Program: Virgin Galactic on Wednesday also said that it entered into a sales agreement under which it may offer and sell shares of its common stock having an aggregate offering price of up to $300 million from time to time pursuant to an "at the market" program.
The proceeds from the program, it said, will be used to accelerate the development and production of its next-generation spaceflight fleet, including an additional carrier plane such as the company&#8217;s VMS Eve dual fuselage jet carrier aircraft and third and fourth Delta Class spaceships.
Price Action: Virgin Galactic shares closed up 3.5% on Wednesday at $7.12. The stock, however, is down by about 85% year-to-date, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="650" height="450" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07041713/newplot-15.jpeg" alt="" class="wp-image-634803" style="width:920px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07041713/newplot-15.jpeg 650w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07041713/newplot-15-300x208.jpeg 300w" sizes="(max-width: 650px) 100vw, 650px" /></figure>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41767169/spacex-completes-400th-successful-falcon-launch-to-date-but-will-miss-target-of-144-launches-in-2024" target="_blank" rel="noreferrer noopener">SpaceX Completes 400th Successful Falcon Launch To Date, But Will Miss Target Of 144 Launches In 2024, Says Company Exec</a></li>
</ul>
Photo courtesy: Shutterstock

SPACE

Tech

SPCE

Richard Branson's Spaceflight Startup Virgin Galactic Sees Stock Surge After Narrowing Q3 Losses, Announces $300M Stock Sale

Needham analyst Joshua Reilly maintains Vertex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) with a Buy and raises the price target from $45 to $60.

Price Target

VERX

Needham Maintains Buy on Vertex, Raises Price Target to $60

Truist Securities analyst Greg Miller maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Hold and raises the price target from $4100 to $4700.

BKNG

Truist Securities Maintains Hold on Booking Holdings, Raises Price Target to $4700

Needham analyst James Ricchiuti maintains Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) with a Buy and raises the price target from $27 to $31.

KRNT

Needham Maintains Buy on Kornit Digital, Raises Price Target to $31

B of A Securities analyst Julien Dumoulin-Smith maintains TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) with a Buy and lowers the price target from $7 to $4.

TPIC

B of A Securities Maintains Buy on TPI Composites, Lowers Price Target to $4

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and maintains $80 price target.

BEAM

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

B of A Securities analyst Dimple Gosa maintains NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Buy and lowers the price target from $65 to $52.

B of A Securities Maintains Buy on NEXTracker, Lowers Price Target to $52

B of A Securities analyst Julien Dumoulin-Smith maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Buy and lowers the price target from $25 to $24.

FLNC

B of A Securities Maintains Buy on Fluence Energy, Lowers Price Target to $24

Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Buy and raises the price target from $17 to $21.

CLBT

Needham Maintains Buy on Cellebrite DI, Raises Price Target to $21

B of A Securities analyst Julien Dumoulin-Smith maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Underperform and lowers the price target from $72 to $62.

ENPH

B of A Securities Maintains Underperform on Enphase Energy, Lowers Price Target to $62

Needham analyst Gil Blum reiterates Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Hold.

FOLD

Needham Reiterates Hold on Amicus Therapeutics

B of A Securities analyst Julien Dumoulin-Smith maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Underperform and lowers the price target from $8 to $7.

B of A Securities Maintains Underperform on Bloom Energy, Lowers Price Target to $7

Piper Sandler analyst Patrick Moley reiterates MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) with a Neutral and maintains $265 price target.

MKTX

Piper Sandler Reiterates Neutral on MarketAxess Holdings, Maintains $265 Price Target

Needham analyst Mike Matson reiterates Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) with a Hold.

SRDX

Needham Reiterates Hold on Surmodics

Amazon Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) CEO Andy Jassy has expressed his disdain for bureaucracy and announced plans to reduce managerial layers within the company
What Happened: In a company-wide meeting on Tuesday, Jassy outlined the company&#8217;s decision to cut down on&nbsp;the number of managers.
The&nbsp;move was aimed at speeding up decision-making processes and preserving Amazon&#8217;s unique culture, which Jassy believes is being stifled by excessive management layers, <a href="https://www.businessinsider.in/tech/news/in-an-all-hands-meeting-amazon-ceo-andy-jassy-tells-employees-why-he-wants-fewer-managers-i-hate-bureaucracy/articleshow/114996847.cms">reported</a> Business Insider, citing a recording of the meeting.
&#8220;The goal again is to&nbsp;allow us to have higher&nbsp;ownership and to move more&nbsp;quickly,&#8221; Jassy stated during the meeting.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/11/41702294/apple-begins-shifting-iphone-17-production-in-india-cooks-china-optimism-and-more-this-week-in-apple?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Begins Shifting iPhone 17 Production In India, Cook&#8217;s China Optimism, And More: This Week In Appleverse</a>
Amazon announced in September that it plans to increase the ratio of individual workers to managers by 15% by the end of the first quarter of 2025.
As part of this initiative, Amazon launched a &#8220;Bureaucracy&nbsp;Mailbox&#8221; last month, where employees&nbsp;can voice concerns about unnecessary processes or rules.
 Jassy revealed that over 150 suggestions received through this platform have already been acted upon.
&#8220;The reality is that the&nbsp;S team and I hate&nbsp;bureaucracy,&#8221; Jassy said, referring to&nbsp;Amazon&#8217;s&nbsp;senior leadership team. &#8220;One of the reasons I&#8217;m still at&nbsp;this company is because it&#8217;s&nbsp;not a political or bureaucratic&nbsp;place.&#8221;
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: For the third quarter of 2024, Amazon reported <a href="https://www.benzinga.com/news/earnings/24/10/41664778/amazon-q3-earnings-highlights-revenue-beat-eps-beat-q4-guidance-new-kindles-significantly-outperfor">net sales of $158.9 billion</a>, up 11% year-over-year, beating Street consensus estimates.
Operating income for the third quarter reached $17.4 billion, an increase from $11.2 billion in the same period last year. Amazon Web Services, or AWS, was the primary driver, contributing $10.4 billion in operating income, compared to $7 billion in the third quarter of the previous year.
Amazon has also been expanding its <a href="https://www.benzinga.com/markets/equities/24/11/41735903/meta-amazon-microsoft-partner-on-defense-ai-initiative">partnerships and initiatives</a>, including a collaboration with Meta Platforms Inc., Microsoft Corp., and others on a defense AI initiative.
However, the company has also faced internal challenges. Last month, AWS CEO Matt Garman defended the company's <a href="https://www.benzinga.com/news/24/10/41394784/amazon-aws-ceo-stands-firm-on-5-day-office-policy-opponents-can-head-for-the-exit-door-there-are-oth">contentious new five-day in-office policy</a>, suggesting that those who oppose it may consider other employment options.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41706934/how-to-master-ios-18s-control-center-tips-to-reset-and-customize-your-iphones-quick-access-hub?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">How To Master iOS 18&#8217;s Control Center: Tips To Reset And Customize Your iPhone&#8217;s Quick Access Hub</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Wikimedia

Media

AMZN

Amazon's Andy Jassy Says 'I Hate Bureaucracy' As He Plans To Slash Managerial Layers: 'The Goal Again Is… To Move More Quickly'

Needham analyst James Ricchiuti reiterates iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) with a Hold.

IRBT

Needham Reiterates Hold on iRobot

Needham analyst Ryan Koontz reiterates Kaltura (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTR#NASDAQ">KLTR</a>) with a Buy and maintains $3 price target.

KLTR

Needham Reiterates Buy on Kaltura, Maintains $3 Price Target

Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) with a Buy and maintains $151 price target.

PRAX

Needham Reiterates Buy on Praxis Precision Medicine, Maintains $151 Price Target

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on NMRA stock, giving a Buy rating yesterday. Graig Suvannavejh has...

Buy Rating Affirmed for Neumora Therapeutics on Innovative Potential and Promising Pipeline

Douglas Tsao, an analyst from H.C. Wainwright, has initiated a new Buy rating on Neumora Therapeutics, Inc. (NMRA). Douglas Tsao has given his Buy ...

Buy Rating Affirmed for Neumora Therapeutics on Navacaprant's Potential in MDD Treatment

Neumora Therapeutics files for mixed securities shelf

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 10/2/2024, According to Top Analysts

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report). The ...

Strong Buy Rating for Neumora Therapeutics Amid Promising Navacaprant Trials and Market Potential

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report) today and set a price target of...

Stifel Nicolaus Remains a Buy on Neumora Therapeutics, Inc. (NMRA)

Neumora Therapeutics: A Story Of A Class II Biotech

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neumora Therapeutics, Inc. (NMRA – Research Report) ...

Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Amylyx Pharmaceuticals Inc (AMLX)

JPMorgan analyst Tessa Romero downgraded Neumora Therapeutics (NMRA) to Neutral from Overweight with a price target of $15, down from $18. Results ...

Neumora Therapeutics downgraded to Neutral from Overweight at JPMorgan

J.P. Morgan analyst Tessa Romero downgraded the rating on Neumora Therapeutics, Inc. (NMRA – Research Report) to a Hold today, setting a price targ...

Comments

Neumora Therapeutics

Neumora Therapeutics (NMRA) Opzioni

Neumora Therapeutics (NASDAQ:NMRA) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO